Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

Next Previous
Trial Profile

A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms WISDOM
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 19 May 2021 Results of pooled analysis from six studies (TONADO 1-2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) comparing the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-to-severe COPD and a predominantly lower exacerbation risk, presented at the 117th International Conference of the American Thoracic Society.
  • 18 May 2016 Results (post hoc analysis, n = 262) assessing lung-function profile before and after the first moderate to severe exacerbation presented at the 112th International Conference of the American Thoracic Society.
  • 18 May 2016 Results of a post hoc subgroup analysis (n=2296) presented at the 112th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top